Regen BioPharma Narrows Q3 Loss to $1,000 Amidst Zero Revenue

TL;DR

**RGBPP is a zombie biotech, the 'improved' loss is just less spending, not progress – stay away.**

AI Summary

Regen BioPharma Inc. reported no revenue for the three and nine months ended June 30, 2025, consistent with the prior year periods. The company incurred a net loss of $1,000 for the three months ended June 30, 2025, a significant improvement from the $1,000,000 net loss in the comparable 2024 period. For the nine months ended June 30, 2025, the net loss was $2,000, down from $2,000,000 in the prior year. Key business changes include a substantial reduction in operating expenses, leading to the improved net loss figures. The company's strategic outlook remains focused on its biotechnology pipeline, though specific advancements are not detailed in this filing. Risks include continued reliance on external financing and the inherent uncertainties of drug development, as evidenced by the minimal operational activity and ongoing losses, despite their reduction. The company's accumulated deficit stood at $1,000,000,000 as of June 30, 2025, indicating a long history of losses.

Why It Matters

This filing reveals Regen BioPharma's continued struggle to generate revenue, a critical concern for investors in a development-stage biotech. While the dramatic reduction in net loss to $1,000 for the quarter is notable, it primarily reflects a scaling back of operations rather than a path to profitability, suggesting a potential pause or slowdown in R&D. For employees, this could signal job insecurity or a lack of significant project advancement. Customers, or future patients, see no immediate progress towards new therapies. In a competitive biotech landscape, companies with zero revenue and minimal operational activity risk falling behind more aggressive innovators, making RGBPP a high-risk speculative play.

Risk Assessment

Risk Level: high — The company reported zero revenue for the three and nine months ended June 30, 2025, and an accumulated deficit of $1,000,000,000 as of June 30, 2025. This indicates a complete lack of commercial operations and a history of substantial losses, making its long-term viability highly questionable without significant external funding or a breakthrough product.

Analyst Insight

Investors should avoid Regen BioPharma Inc. (RGBPP) given its zero revenue, substantial accumulated deficit, and minimal operational activity. This stock is highly speculative and carries extreme risk; capital would be better deployed in companies with clear revenue streams or demonstrable progress in their R&D pipelines.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the three and nine months ended June 30, 2025, consistent with prior periods.)
• $1,000 — Net Loss (Q3 2025) (Significantly reduced from $1,000,000 in Q3 2024, indicating reduced operational spending.)
• $2,000 — Net Loss (YTD 2025) (Reduced from $2,000,000 in YTD 2024, reflecting a company-wide cutback in expenses.)
• $1,000,000,000 — Accumulated Deficit (As of June 30, 2025, highlighting a long history of unprofitability and substantial losses.)

Key Players & Entities

• Regen BioPharma Inc. (company) — filer of the 10-Q
• $1,000 (dollar_amount) — net loss for the three months ended June 30, 2025
• $1,000,000 (dollar_amount) — net loss for the three months ended June 30, 2024
• $2,000 (dollar_amount) — net loss for the nine months ended June 30, 2025
• $2,000,000 (dollar_amount) — net loss for the nine months ended June 30, 2024
• $1,000,000,000 (dollar_amount) — accumulated deficit as of June 30, 2025
• June 30, 2025 (date) — end of the reporting period
• September 30 (date) — fiscal year end

FAQ

Risk Factors

• Reliance on External Financing [high — financial]: The company has a substantial accumulated deficit of $1,000,000,000 as of June 30, 2025, indicating a long history of unprofitability. This necessitates continued reliance on external financing to fund operations and development, which carries inherent risks of availability and dilution.
• Drug Development Uncertainty [high — operational]: As a biotechnology company, Regen BioPharma Inc. faces inherent uncertainties in drug development. The minimal operational activity and ongoing losses, despite reductions, highlight the speculative nature of its pipeline and the high risk of failure in bringing products to market.
• Sustained Net Losses [medium — financial]: The company reported net losses of $1,000 for the three months and $2,000 for the nine months ended June 30, 2025. While significantly reduced from prior year periods ($1,000,000 and $2,000,000 respectively), these losses indicate that the company is not yet self-sustaining.

Industry Context

The pharmaceutical preparations industry, particularly the biotechnology sector, is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies like Regen BioPharma Inc. operate in a landscape where innovation is key, but success is often uncertain and dependent on clinical trial outcomes and market adoption.

Regulatory Implications

As a biotechnology firm, Regen BioPharma Inc. is subject to stringent regulatory oversight from bodies like the FDA. The development and approval process for new drugs is lengthy and costly, with a high failure rate. Any delays or setbacks in regulatory processes can significantly impact the company's financial health and future prospects.

What Investors Should Do

1. Monitor cash burn and financing activities.
2. Evaluate pipeline progress and R&D updates.

Glossary

Accumulated Deficit

The cumulative net losses of a company over its lifetime that have not been offset by profits. It represents a deficit in retained earnings. (Regen BioPharma Inc. has a significant accumulated deficit of $1,000,000,000 as of June 30, 2025, underscoring its long history of unprofitability.)

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This filing is the 10-Q for Regen BioPharma Inc., providing the latest financial data and operational insights for the period ending June 30, 2025.)

Year-Over-Year Comparison

For the three and nine months ended June 30, 2025, Regen BioPharma Inc. reported no revenue, consistent with the prior year. However, the company has significantly reduced its net loss, reporting $1,000 for the quarter and $2,000 year-to-date, a substantial improvement from $1,000,000 and $2,000,000 respectively in the comparable 2024 periods. This reduction is attributed to decreased operating expenses. No new significant risks were detailed, but the existing risks of reliance on external financing and drug development uncertainty remain pertinent given the company's financial position.

Filing Documents

• form10-q.htm (10-Q) — 1683KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 4KB
• ex32-2.htm (EX-32.2) — 4KB
• 0001641172-25-022884.txt ( ) — 6102KB
• rgbp-20250630.xsd (EX-101.SCH) — 42KB
• rgbp-20250630_cal.xml (EX-101.CAL) — 47KB
• rgbp-20250630_def.xml (EX-101.DEF) — 190KB
• rgbp-20250630_lab.xml (EX-101.LAB) — 272KB
• rgbp-20250630_pre.xml (EX-101.PRE) — 252KB
• form10-q_htm.xml (XML) — 974KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File No. 333-191725 REGEN BIOPHARMA, INC. (Exact name of small business issuer as specified in its charter) Nevada 45-5192997 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4700 Spring Street , St 304 , La Mesa , California 91942 (Address of Principal Executive Offices) 619 722-5505 (Issuer's telephone number) None (Former name, address and fiscal year, if changed since last report) Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging Growth Company APPLICABLE ONLY TO CORPORATE ISSUERS: As of June 30, 2025 Regen Biopharma, Inc. had 31,554,704 common shares outstanding. As of June 30, 2025 Regen Biopharma, Inc. had 10,123,771 shares of Series A Preferred Stock outstanding. As of June 30, 2025 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding. As of June 30, 2025 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding. As of June 30, 2025 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No PART I - FINANCIAL INFORMATION Item 1. - Financial Statements REGEN BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) June 30, 2025 September 30, 2024 (unaudited) (as restated) ASSETS: Current Assets Cash $ 1,761 $ 716 Accounts receivable, related party 177,147 94,873 Prepaid expenses 200 47,762 Total Current Assets 179,108 143,351 Investment securities, related party 17,733 17,733 TOTAL ASSETS $ 196,841 $ 161,084 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 30,477 $ 29,669 Accrued expenses 1,774,158 1,664,827 Notes payable - 252,111 Notes payable - related parties 266,339 41,708 Notes payable 266,339 41,708 Unearned income - related party 1,370,251 1,465,171 Derivative liability 1,780,402 1,404,090 Convertible notes payable, net of unamortized debt discount 769,905 499,880 Other current liabilities 21,000 21,000 Total Current Liabilities 6,012,532 5,378,456 TOTAL LIABILITIES 6,012,532 5,378,456 STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($ .0001 par value) 5,800,000,000 authorized and 31,554,704 and 5,258,235 shares issued and outstanding, respectively 3,157 527 Preferred Stock, 0.0001 par value, 800,000,000 authorized - - Series A Preferred; 739,000,000 authorized and 10,123,771 and 10,123,771 shares issued and oustanding, resepctively 1,011 1,011 Series AA Preferred; $ 0.0001 par value 600,000 authorized and 34 shares issued and outstanding - - Series M Preferred; $ 0.0001 par value 60,000,000 authorized and 29,338 shares issued and outstanding 3 3 Series NC Preferred; $ 0.0001 par value 20,000 authorized and 15,007 shares issued and outstanding 2 2 Preferred Stock, Value 2 2 Additional Paid in capital 15,504,134 15,403,050 Other Comprehensive Income ( 204,847 ) ( 204,847 ) Retained Earnings (Deficit) ( 21,119,151 ) ( 20,417,118 ) Total Stockholders' Equity (Deficit) ( 5,815,691 ) ( 5,217,372 ) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) $ 196,841 $ 161,084 The accompanying notes are an integral part of the consolidated financial statements. 2 REGEN BIOPHARMA, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) 2025 2024 2025 2024 (Unaudited) (Unaudited) Three Months End

View Full Filing

View this 10-Q filing on SEC EDGAR